Clinical Trial Update: To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study evaluating whether higher-dose OXN PR is equivalent to lower-dose OXN PR in pain relief and bowel function in patients with cancer pain or non-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Pain
• Non-cancer Pain

Drugs mentioned

• Oxycodone/naloxone prolonged-release (OXN PR) (oxycodone/naloxone)

Snippet

Sponsor: Mundipharma Research GmbH & Co KG | Conditions: Malignant Pain, Non-malignant Pain | Phase 2, Phase 3 | Status: COMPLETED